Evidence map›Paper›PMID 26170307›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

TACI deficiency leads to alternatively activated macrophage phenotype and susceptibility to Leishmania infection.

Windy R Allman, Ranadhir Dey, Lunhua Liu, Shafiuddin Siddiqui, Adam S Coleman, Parna Bhattacharya, Masahide Yano, Kadriye Uslu, Kazuyo Takeda, Hira L Nakhasi and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Inflammatory CD11bPathogens (Basel, Switzerland) · 2024
    Article
  9. Inborn Errors of Immunity and Cytokine Storm Syndromes.Advances in experimental medicine and biology · 2024
    Review
  10. Article
  11. Review
  12. Unwinding the mechanism of macrophage repolarization potential ofFrontiers in cellular and infection microbiology · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Frontiers in immunology · 2021
    Article
  17. Article
  18. Review
  19. TACI Constrains TiScience · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Windy R AllmanLaboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Silver Spring, MD 20993;
Ranadhir DeyDivision of Emerging and Transfusion Transmitted Diseases, US Food and Drug Administration, Silver Spring, MD 20993;
Lunhua LiuLaboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Silver Spring, MD 20993;
Shafiuddin SiddiquiLaboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Silver Spring, MD 20993;
Adam S ColemanLaboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Silver Spring, MD 20993;
Parna BhattacharyaDivision of Emerging and Transfusion Transmitted Diseases, US Food and Drug Administration, Silver Spring, MD 20993;
Masahide YanoLaboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Silver Spring, MD 20993;
Kadriye UsluLaboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Silver Spring, MD 20993;
Kazuyo TakedaMicroscopy and Imaging Core Facility, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993.
Hira L NakhasiDivision of Emerging and Transfusion Transmitted Diseases, US Food and Drug Administration, Silver Spring, MD 20993;
Mustafa AkkoyunluLaboratory of Bacterial Polysaccharides, Division of Bacterial Parasitic and Allergenic Products, US Food and Drug Administration, Silver Spring, MD 20993; mustafa.akkoyunlu@fda.hhs.gov.
United States Food and Drug Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TNF family member, transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI), is a key molecule for plasma cell maintenance and is required in infections where protection depends on antibody response. Here, we report that compared with WT mouse, TACI KO Μϕs expressed lower levels of Toll-like receptors (TLRs), CD14, myeloid differentiation primary response protein 88, and adaptor protein Toll/IL-1 receptor domain-containing adapter-inducing IFN-β and responded poorly to TLR agonists. Analysis of Μϕ phenotype revealed that, in the absence of TACI, Μϕs adapt the alternatively activated (M2) phenotype. Steady-state expression levels for M2 markers IL-4Rα, CD206, CCL22, IL-10, Arg1, IL1RN, and FIZZ1 were significantly higher in TACI KO Μϕ than in WT cells. Confirming their M2 phenotype, TACI-KO Mϕs were unable to control Leishmania major infection in vitro, and intradermal inoculation of Leishmania resulted in a more severe manifestation of disease than in the resistant C57BL/6 strain. Transfer of WT Μϕs to TACI KO mice was sufficient to significantly reduce disease severity. TACI is likely to influence Mϕ phenotype by mediating B cell-activating factor belonging to the TNF family (BAFF) and a proliferation inducing ligand (APRIL) signals because both these ligands down-regulated M2 markers in WT but not in TACI-deficient Μϕs. Moreover, treatment of Μϕs with BAFF or APRIL enhanced the clearance of Leishmania from cells only when TACI is expressed. These findings may have implications for understanding the shortcomings of host response in newborns where TACI expression is reduced and in combined variable immunodeficiency patients where TACI signaling is ablated.

Indexed as

AnimalsB-Cell Activating FactorCell ProliferationGene Expression RegulationLeishmaniaLeishmaniasisLigandsLipopolysaccharide ReceptorsMacrophagesMiceMice, Inbred C57BLMice, KnockoutPhenotypePhosphorylationSignal TransductionTransmembrane Activator and CAML Interactor ProteinB-Cell Activating FactorLigandsLipopolysaccharide ReceptorsTnfrsf13b protein, mouseTnfsf13b protein, mouseTransmembrane Activator and CAML Interactor ProteinTumor Necrosis Factor Ligand Superfamily Member 13APRILBAFFLeishmaniamacrophageTACI

Identifiers

PMID26170307
PMCPMC4522803
OpenAlexW1799271643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.